Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease

Doherty GA, Miksad RA, Cheifetz AS, Moss AC

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21905173

DOI
10.1002/ibd.21904

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
6-Mercaptopurine /economics /therapeutic use; Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Antibodies, Monoclonal /economics /therapeutic use; Azathioprine /economics /therapeutic use; Cost-Benefit Analysis; Crohn Disease /drug therapy /economics /surgery; Decision Trees; Health Care Costs; Humans; Immunosuppressive Agents /economics /therapeutic use; Infliximab; Mesalamine /economics /therapeutic use; Monte Carlo Method; Postoperative Period; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Secondary Prevention

AccessionNumber
22012032357

Date bibliographic record published
08/01/2013